223 related articles for article (PubMed ID: 20796312)
21. A Combination Antibiogram Evaluation for
Puzniak L; DePestel DD; Srinivasan A; Ye G; Murray J; Merchant S; DeRyke CA; Gupta V
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30917987
[No Abstract] [Full Text] [Related]
22. [Guidelines for treatment of pneumonia in intensive care units].
Emmi V
Infez Med; 2005; Suppl():7-17. PubMed ID: 16801748
[TBL] [Abstract][Full Text] [Related]
23. Hospital-acquired pneumonia in critically ill patients: factors associated with episodes due to imipenem-resistant organisms.
Leroy O; d'Escrivan T; Devos P; Dubreuil L; Kipnis E; Georges H
Infection; 2005 Jun; 33(3):129-35. PubMed ID: 15940413
[TBL] [Abstract][Full Text] [Related]
24. Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program.
Lob SH; Hackel MA; Kazmierczak KM; Hoban DJ; Young K; Motyl MR; Karlowsky JA; Sahm DF
Diagn Microbiol Infect Dis; 2017 Jun; 88(2):171-176. PubMed ID: 28291628
[TBL] [Abstract][Full Text] [Related]
25. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia.
Chung DR; Song JH; Kim SH; Thamlikitkul V; Huang SG; Wang H; So TM; Yasin RM; Hsueh PR; Carlos CC; Hsu LY; Buntaran L; Lalitha MK; Kim MJ; Choi JY; Kim SI; Ko KS; Kang CI; Peck KR;
Am J Respir Crit Care Med; 2011 Dec; 184(12):1409-17. PubMed ID: 21920919
[TBL] [Abstract][Full Text] [Related]
26. Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance.
Fernández-Barat L; Ferrer M; De Rosa F; Gabarrús A; Esperatti M; Terraneo S; Rinaudo M; Li Bassi G; Torres A
J Infect; 2017 Feb; 74(2):142-152. PubMed ID: 27865895
[TBL] [Abstract][Full Text] [Related]
27. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.
Stone GG; Newell P; Gasink LB; Broadhurst H; Wardman A; Yates K; Chen Z; Song J; Chow JW
J Antimicrob Chemother; 2018 Sep; 73(9):2519-2523. PubMed ID: 29912399
[TBL] [Abstract][Full Text] [Related]
28. Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.
Bassetti M; Castaldo N; Cattelan A; Mussini C; Righi E; Tascini C; Menichetti F; Mastroianni CM; Tumbarello M; Grossi P; Artioli S; Carannante N; Cipriani L; Coletto D; Russo A; Digaetano M; Losito AR; Peghin M; Capone A; Nicolè S; Vena A;
Int J Antimicrob Agents; 2019 Apr; 53(4):408-415. PubMed ID: 30415002
[TBL] [Abstract][Full Text] [Related]
29. Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.
Kresken M; Körber-Irrgang B; Korte-Berwanger M; Pfennigwerth N; Gatermann SG; Seifert H;
Int J Antimicrob Agents; 2020 Jun; 55(6):105959. PubMed ID: 32325200
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for hospital-acquired pneumonia caused by imipenem-resistant Pseudomonas aeruginosa in an intensive care unit.
Furtado GH; Gales AC; Perdiz LB; Santos AE; Wey SB; Medeiros EA
Anaesth Intensive Care; 2010 Nov; 38(6):994-1001. PubMed ID: 21226427
[TBL] [Abstract][Full Text] [Related]
31. An overview of cilastatin + imipenem + relebactam as a therapeutic option for hospital-acquired and ventilator-associated bacterial pneumonia: evidence to date.
Sellarès-Nadal J; Eremiev S; Burgos J; Almirante B
Expert Opin Pharmacother; 2021 Aug; 22(12):1521-1531. PubMed ID: 34120547
[No Abstract] [Full Text] [Related]
32. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
33. Characteristics of carbapenem-resistant Pseudomonas aeruginosa strains in patients with ventilator-associated pneumonia in intensive care units.
Vitkauskienė A; Skrodenienė E; Dambrauskienė A; Bakšytė G; Macas A; Sakalauskas R
Medicina (Kaunas); 2011; 47(12):652-6. PubMed ID: 22370463
[TBL] [Abstract][Full Text] [Related]
34. Antimicrobial-resistant Pseudomonas aeruginosa and Acinetobacter baumannii From Patients With Hospital-acquired or Ventilator-associated Pneumonia in Vietnam.
Biedenbach DJ; Giao PT; Hung Van P; Su Minh Tuyet N; Thi Thanh Nga T; Phuong DM; Vu Trung N; Badal RE
Clin Ther; 2016 Sep; 38(9):2098-105. PubMed ID: 27612610
[TBL] [Abstract][Full Text] [Related]
35. Emergence of Antimicrobial Resistance among Pseudomonas aeruginosa: Implications for Therapy.
Lynch JP; Zhanel GG; Clark NM
Semin Respir Crit Care Med; 2017 Jun; 38(3):326-345. PubMed ID: 28578556
[TBL] [Abstract][Full Text] [Related]
36. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.
Fink MP; Snydman DR; Niederman MS; Leeper KV; Johnson RH; Heard SO; Wunderink RG; Caldwell JW; Schentag JJ; Siami GA
Antimicrob Agents Chemother; 1994 Mar; 38(3):547-57. PubMed ID: 8203853
[TBL] [Abstract][Full Text] [Related]
37. Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia.
Khawcharoenporn T; Chuncharunee A; Maluangnon C; Taweesakulvashra T; Tiamsak P
Int J Antimicrob Agents; 2018 Dec; 52(6):828-834. PubMed ID: 30236956
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa.
Paladino JA; Sunderlin JL; Forrest A; Schentag JJ
J Antimicrob Chemother; 2003 Sep; 52(3):457-63. PubMed ID: 12888598
[TBL] [Abstract][Full Text] [Related]
39. Nosocomial Acinetobacter pneumonia: Treatment and prognostic factors in 356 cases.
Özvatan T; Akalın H; Sınırtaş M; Ocakoğlu G; Yılmaz E; Heper Y; Kelebek N; İşçimen R; Kahveci F
Respirology; 2016 Feb; 21(2):363-9. PubMed ID: 26635315
[TBL] [Abstract][Full Text] [Related]
40. The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs.
Borgatta B; Gattarello S; Mazo CA; Imbiscuso AT; Larrosa MN; Lujàn M; Rello J
Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2155-2163. PubMed ID: 28624864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
